Evaluation of Various Laboratory Methods for the Diagnosis of Clostridium difficile Infection Yousun Chung1, Ji Yeon Sung1, Ho Eun Chang2, Soon Hee Choi2,

Slides:



Advertisements
Similar presentations
Building on Patient Safety Clostridium difficile practice opportunities Mary Ellen Scales RN MSN CIC Baystate Medical Center.
Advertisements

Microbiology without culture - is this the future? Professor Brian Duerden Inspector of Microbiology and Infection Control, Department of Health.
Diagnosing Clostridium difficile. Tim Planche St. George’s Healthcare NHS Trust St. George’s, University of London.
TechLab Diarrheal Diseases in Underdeveloped Countries Worldwide Problem More than 10,000 deaths per day On average, about 18 diarrheal episodes per year.
NEW Product MAY 2006 STREPTO B ID NEW chromogenic media available ! STREPTO B ID NEW PRODUCT in the bMx offer SECOND in the NEW PREVENTION range dedicated.
STUDY DESIGN FOR DIAGNOSTIC STUDY FOR MELIOIDOSIS Dr Direk Limmathurotsakul, MD MSc PhD.
A.M. Freydiere 1, T. Goyard 1, C. Ploton 1, D. Thouvenot 2, A. Rousson 1 and F. Vandenesch 1 1 Hôpital Debrousse, Hospices.
Diagnostic Microbiology and Immunology
Alfred DeMaria, Jr., M.D. Medical Director Bureau of Infectious Disease Prevention, Response and Services State Epidemiologist C. Difficile Testing Recommendations.
MICR 420 Emerging and Re-Emerging Infectious Diseases Lecture 4: C. difficile Dr. Nancy McQueen & Dr. Edith Porter.
Leav, B. A., et al.(2010) “Serum Anti-toxin B Antibody Correlates with Protection from Recurrent Clostridium Difficile Infection (CDI)”. Vaccine 28:
Clostridium difficile disease. A review of laboratory investigations.
CURRENT STATUS Consultant Microbiologist with additional responsibilities of Head of The Department and Director of National Leptospirosis Reference Unit.
Lab Diagnosis of Viruses Dr Syed Suhail Ahmed College of Medicine Qassim University.
Novel chimeric vaccines against Clostridium difficile infection
Infection and Disease Fungi Parasites Nosocomial infection Diagnosis of infectious disease.
RESULTS INTRODUCTION METHODS CONCLUSION  Since the early 90’s Enterococcus faecium resistant to Glycopeptides (GRE) have emerged in several French hospitals.
WHEN DID THE NEW VARIANT OF CHLAMYDIA TRACHOMATIS (nvCT) EMERGE IN ÖREBRO COUNTY, SWEDEN? – A STATISTICAL EVALUATION OF THE POSITIVITY RATES FROM 1999.
Clostridium difficile Separating key facts from fiction S P Borriello
Screening.  “...the identification of unrecognized disease or defect by the application of tests, examinations or other procedures...”  “...sort out.
Jane Stockley Chris Catchpole Carole Clive November 2012.
COMPARISON OF LABORATORY DIAGNOSTIC PROCEDURES FOR DETECTION OF MYCOPLASMA PNEUMONIAE IN COMMUNITY OUTBREAKS KATHLEEN A. THURMAN, NICHOLAS D. WALTER, STEPHANIE.
Shiga Toxin E. coli Rapid detection is key!. Intestinal Diseases Difficult to diagnose clinically – Most have very similar symptoms Treatment & patient.
Evaluation of Real-time PCR for Atypical pneumonia Wantana Paveenkittiporn 1 *, Anusak Kerdsin 2, Apimon Jirapongsathorn 1, Kanthana Boonsang 1, Saowalak.
Point of Care Diagnostics for Hospital Acquired Infections (HAIs): Health Economics Perspective Detection & Identification of Infectious Agents (DIIA)
Clostridium difficile Infection Fellow 이시내. Clostridium difficile  An anaerobic gram-positive, spore-forming, toxin-producing bacillus.  Transmitted.
Q fever from Unknown Febrile Patients in Korea
Comparison the laboratory diagnosis of human brucellosis Young Sill Choi*, Young Rok Kim, Sang Hee Park, Soo Kyung Shim, Kyu Jam Hwang and Mi Yeoun Park.
Clostridium difficile infection (CDI) in the ICU and Clostridium difficile outcomes in the PROSPECT Main Trial Erick Duan MD FRCPC Presented at the CCCTG.
Foundations in Microbiology Seventh Edition
Title of the Change Project
Ch.12 Immunology Applications
PREMARKET EVALUATION OF THE BD MAXTM CLOSTRIDIUM DIFFICILE PCE ASSAY
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
RESULTS AND DISCUSSION
Objectives Methods Results Conclusions Contact 64
Evolution in the Type of Diagnostic Tests Used in Quebec, Canada,
Impact of the Type of Diagnostic Assay on Clostridium difficile Infection and Complication Rates in a Mandatory Reporting Program Yves Longtin, Sylvie.
서울대학교 의과대학 검사의학교실1, 분당서울대학교병원 진단검사의학과2
2011 American Society for Microbiology Meeting
C. difficile Detection and the Importance of Proper Specimen Collection and Testing [Name] [Title]
Laboratory Diagnosis of Infectious Diseases
مالاریا جنس پلاسمودیوم: مالاریا شایعترین بیماری انگلی دنیا است.
Richard Steece, Ph.D., D(ABMM)
P.-Y. Lévy  Clinical Microbiology and Infection 
Detection of bacteria in blood products
PCP: Diagnosis Dr. Rita O. Oladele Consultant Clinical Microbiologist
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Laboratory Diagnosis of Clostridium difficile Infection
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
C.Difficile update – what you need to know in Primary Care
F. Barbut, M. Delmée, J. S. Brazier, J. C. Petit, I. R. Poxton, M
New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to.
Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm  C. Beaulieu, L.-L.
Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland  D. Drudy, N. Harnedy, S. Fanning, R. O'Mahony,
Jennifer R. O'Connor, Stuart Johnson, Dale N. Gerding  Gastroenterology 
Application of Isothermal Helicase-Dependent Amplification with a Disposable Detection Device in a Simple Sensitive Stool Test for Toxigenic Clostridium.
Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients  S. Erb, R. Frei,
F. Barbut, L. Surgers, C. Eckert, B. Visseaux, M. Cuingnet, C
Precipitation Tests Precipitation Soluble Ab Immunodiffusion.
M.H. Wilcox  Clinical Microbiology and Infection 
Application of Nuclear Magnetic Resonance to Detect Toxigenic Clostridium difficile from Stool Specimens  Paul Yang, Sara Hash, Katherine Park, Charlene.
Laboratory diagnosis of Clostridium difficile disease
European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection  M.J.T.
R. Alonso, C. Muñoz, T. Peláez, E. Cercenado, M. Rodríguez-Creixems, E
Detection of nosocomial Clostridium difficile infections with toxigenic strains despite negative toxin A and B testing on stool samples  J. Stahlmann,
E.J. Kuijper, B. Coignard, P. Tüll  Clinical Microbiology and Infection 
Measuring the Cost of Overtesting and Overdiagnosis of C
Comparison between CLIA & ELISA
C. diff Testing Stewardship
Presentation transcript:

Evaluation of Various Laboratory Methods for the Diagnosis of Clostridium difficile Infection Yousun Chung1, Ji Yeon Sung1, Ho Eun Chang2, Soon Hee Choi2, Yun Ji Hong1, Taek Soo Kim1,2, Kyoung Un Park1,2, Junghan Song1,2, Eui Chong Kim1 1Department of Laboratory Medicine, Seoul National University College of Medicine; 2Department of Laboratory Medicine, Seoul National University Bundang Hospital

Clostridium difficile Infection (CDI) BACKGROUND Clostridium difficile Infection (CDI) Leading cause of health care-associated diarrhea Clinical features overlapping with other antibiotic-associated diarrhea Increase in the number of cases and in the severity Emergence of hypervirulent toxigenic strain, BI/NAP1/027 Prompt CDI identification to prevent disease progression and to reduce additional nosocomial cases Lack of rapid, accurate, and inexpensive diagnostic test

Laboratory Diagnosis of CDI BACKGROUND Laboratory Diagnosis of CDI Culture Labor-intensive, long TAT Enzyme immunoassay (EIA) Easy, rapid TAT, variable performance Cell cytotoxicity neutralization assay (CCNA) Labor-intensive, long TAT, Expensive cell lines, Interpretation Molecular-based assays High sensitivity and specificity, short TAT, Expensive

Aims Compare the performance of different laboratory methods for the diagnosis of CDI Evaluate real-time PCR assays in diagnosis of CDI

Materials and Methods Materials Laboratory diagnostic methods 188 stool specimens from Seoul National University Bundang Hospital 52 C. difficile colonies: randomly selected Laboratory diagnostic methods chromID C. difficile (bioMérieux) Cell cytotoxicity neutralization assay (CCNA) VIDAS C. difficile Toxin A & B (bioMérieux) RIDA QUICK C. difficile Toxin A/B (R-Biopharm) RIDA SCREEN C. difficile Toxin A/B (R-Biopharm) RIDA GENE C. difficile & Toxin A/B (R-Biopharm) IMDx C. difficile (Abbott)

chromID C. difficile (bioMérieux) MATERIALS and METHODS chromID C. difficile (bioMérieux) Detection of β-glucosidase producing C. difficile strains Typical grey to black color of colonies VIDAS C. difficile Toxin A & B (bioMérieux) Enzyme linked fluorescent immunoassay Qualitative detection of C. difficile toxin A/B

Cell cytotoxicity neutralization assay (CCNA) MATERIALS and METHODS Cell cytotoxicity neutralization assay (CCNA) Inoculation of stool sample onto cultured human fibroblasts Reading in 2 hrs, 6 hrs, 24hrs, and 48hrs Cytopathic effect of toxin causes the fibroblasts to round up Absence of cytopathic effect with the anti-toxin Considered as a gold standard for C. difficile toxin Labor-intensive, long TAT, Expensive cell lines, Interpretation

RIDASCREEN® C. difficile Toxin A/B (R-Biopharm) MATERIALS and METHODS RIDA®QUICK C. difficile Toxin A/B (R-Biopharm) Immunochromatographic rapid assay Determination of Toxin A and Toxin B with anti-Toxin A and anti-Toxin B antibodies RIDASCREEN® C. difficile Toxin A/B (R-Biopharm) Enzyme immunoassay Detection of both toxin A/B with monoclonal antibodies

RIDA®GENE C. difficile & Toxin A/B (R-Biopharm) MATERIALS and METHODS RIDA®GENE C. difficile & Toxin A/B (R-Biopharm) Real-time PCR Detection of C. difficile (16S rRNA) and toxin (tcdA/tcdB genes) IMDx C. difficile (Abbott) Real-time PCR Detection of conserved regions of tcdA and tcdB genes

CCNA as the gold standard RESULTS CCNA as the gold standard chromID VIDAS RIDA QUICK SCREEN GENE IMDx Sensitivity Stool 79.1 74.6 10.4 47.8 89.6 96.9 Colony 75 12.5 59.4 Specificity 23.8 69 100 95.2 76.2 76.9 57.9 94.7 89.5 68.4 63.2 PPV 62.4 79.4 94.1 85.7 87.5 80 90.5 83.8 81.6 NPV 41.7 63 41.2 53.3 82.1 93.8 39.1 56.7 92.9 92.3

Real-time PCR assays as the gold standard RESULTS Real-time PCR assays as the gold standard chromID VIDAS RIDA QUICK SCREEN CCNA Sensitivity Stool 74.3 65.7 10.0 45.7 89.1 Culture 68.4 13.2 55.3 Specificity 15.9 56.8 100.0 95.5 84.2 50.0 92.9 PPV 58.4 70.7 94.1 90.5 78.8 NPV 28.0 51.0 41.1 52.5 82.1 36.8 29.8 43.3

Conclusions Enzyme immunoassay methods showed variable performance VIDAS showed relatively high sensitivity Real-time PCR methods showed high sensitivity and specificity Do not detect the presence of toxin itself Difficult choices to balance test performance and cost chromID + VIDAS → Molecular assay